On January 5, 2024, Elevation Oncology, Inc. (the “Company”) issued a press release announcing program updates and upcoming milestones. The Company announced that it plans to provide an update from its ongoing Phase 1 trial of EO-3021, an anti-Claudin 18.2 antibody-drug conjugate (“ADC”), in mid-2024, with additional data expected in the first half of 2025. The Company also announced that it plans to evaluate EO-3021 in combination with both immunotherapy and targeted agents, with further details on its combination study expected in the first half of 2024. In addition, the Company announced that it is currently evaluating a HER3-targeting ADC program and plans to nominate a development candidate in 2024. The Company further reported that it expects its cash, cash equivalents and marketable securities as of September 30, 2023 to be sufficient to fund its current operations into the second half of 2025.
This current report contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, anticipated clinical and preclinical development activities, expected timing of announcements of clinical results and trial details and the Company’s expectations about its cash runway. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. These forward-looking statements may be accompanied by such words as “aim,” “anticipate,” “believe,” “could,” “estimate,” “expect,” “forecast,” “goal,” “intend,” “may,” “might,” “plan,” “possible,” “potential,” “will,” “would,” and other words and terms of similar meaning. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, the Company cannot guarantee future events, results, actions, levels of activity, performance or achievements, and the timing and results of biotechnology development and potential regulatory approval is inherently uncertain. Further information on potential risk factors that could affect the Company’s business and financial results are detailed in its most recent Quarterly Report on Form 10-Q for the quarter ended September 30, 2023, filed with the Securities and Exchange Commission (SEC), and its other reports as filed with the SEC. The Company undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.